Sharon Vidal - Illumina Global Responsibility

ILMN Stock  USD 136.99  5.31  4.03%   

Executive

Sharon Vidal is Global Responsibility of Illumina
Address 5200 Illumina Way, San Diego, CA, United States, 92122
Phone858 202 4500
Webhttps://www.illumina.com

Illumina Management Efficiency

The company has return on total asset (ROA) of 0.0262 % which means that it generated a profit of $0.0262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3951) %, meaning that it created substantial loss on money invested by shareholders. Illumina's management efficiency ratios could be used to measure how well Illumina manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.24. In addition to that, Return On Capital Employed is likely to grow to -0.12. At this time, Illumina's Debt To Assets are very stable compared to the past year. As of the 22nd of November 2024, Fixed Asset Turnover is likely to grow to 3.35, while Non Currrent Assets Other are likely to drop about 123.4 M.
Illumina currently holds 2.26 B in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Illumina has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Illumina's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Karen NelsonThermo Fisher Scientific
N/A
Hal GibsonCaredx Inc
N/A
Ryan SnyderThermo Fisher Scientific
N/A
Brian BaranickEXACT Sciences
46
Stacey FollonCaredx Inc
N/A
Sarah CondellaEXACT Sciences
43
James ThorburnTwist Bioscience Corp
68
Aaron BloomerEXACT Sciences
38
Jeffrey NovackCaredx Inc
41
Jessica MengCaredx Inc
N/A
Michael EricksonIDEXX Laboratories
50
Kashif RathoreCaredx Inc
N/A
Rafael TejadaThermo Fisher Scientific
N/A
Robert SchuerenNatera Inc
62
Daniel LLMNatera Inc
55
Michael JohnsonIDEXX Laboratories
46
William IVDanaher
56
Kerry BennettIDEXX Laboratories
N/A
Philip BinnsAgilent Technologies
N/A
Robert IIIWaters
N/A
Ken GradyIDEXX Laboratories
N/A
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company was incorporated in 1998 and is based in San Diego, California. Illumina operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 9800 people. Illumina (ILMN) is traded on NASDAQ Exchange in USA. It is located in 5200 Illumina Way, San Diego, CA, United States, 92122 and employs 10,590 people. Illumina is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Illumina Leadership Team

Elected by the shareholders, the Illumina's board of directors comprises two types of representatives: Illumina inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Illumina. The board's role is to monitor Illumina's management team and ensure that shareholders' interests are well served. Illumina's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Illumina's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Hoffman, Segment Sequencing
Francis deSouza, Pres and Director
Jacob Thaysen, CEO Director
Pat Leckman, Interim Officer
Charles Dadswell, Senior Vice President General Counsel, Secretary
Ankur Dhingra, Chief Officer
Nicole Berry, Head RegionAmericas
Mena Farag, Senior Specialist
Scott Ericksen, VP Officer
Kevin Pegels, Chief Operations
Charles Esq, Senior Counsel
Joydeep MBA, Executive Officer
Sharon Vidal, Global Responsibility
Jakob Wedel, Chief Staff
Bas Verhoef, Interim RegionEurope
Sallilyn Schwartz, Vice Relations
Susan Tousi, Chief Officer
Kathryne Reeves, Chief Officer
Scott Davies, Interim Secretary
Ankur CPA, Chief Officer
Steven Barnard, Chief Officer
Alexander MD, CTO Devel
Stephanie Campos, President
Carissa Rollins, Chief Officer
Jenny Zheng, Head China
Gretchen Weightman, Middle Pacific

Illumina Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Illumina a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Illumina

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Illumina position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Illumina will appreciate offsetting losses from the drop in the long position's value.

Moving against Illumina Stock

  0.69VCNX VaccinexPairCorr
  0.58DTIL Precision BioSciencesPairCorr
  0.53VALN Valneva SE ADR Downward RallyPairCorr
  0.52ME 23Andme HoldingPairCorr
  0.51DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Illumina could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Illumina when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Illumina - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Illumina to buy it.
The correlation of Illumina is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Illumina moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Illumina moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Illumina can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Illumina offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Illumina's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Illumina Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Illumina Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
(9.98)
Revenue Per Share
27.654
Quarterly Revenue Growth
(0.04)
Return On Assets
0.0262
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.